Metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease also decreases at thyroid

MLA

Akiko Tamura, et al. “Metaiodobenzylguanidine (MIBG) Uptake in Parkinson’s Disease Also Decreases at Thyroid.” Annals of Nuclear Medicine, vol. 19, May 2005, pp. 225–29. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....29cdbc2d6dd3582985b84c54ae1aa877&authtype=sso&custid=ns315887.

APA

Akiko Tamura, Masakuni Kameyama, Masaya Oda, Kazuto Nishinaka, Fukashi Udaka, Tamotsu Kubori, & Hideaki Matsui. (2005). Metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease also decreases at thyroid. Annals of Nuclear Medicine, 19, 225–229.

Chicago

Akiko Tamura, Masakuni Kameyama, Masaya Oda, Kazuto Nishinaka, Fukashi Udaka, Tamotsu Kubori, and Hideaki Matsui. 2005. “Metaiodobenzylguanidine (MIBG) Uptake in Parkinson’s Disease Also Decreases at Thyroid.” Annals of Nuclear Medicine 19 (May): 225–29. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....29cdbc2d6dd3582985b84c54ae1aa877&authtype=sso&custid=ns315887.